Sectors
TNGX
Tango Therapeutics, Inc.
22.82
1 x 21.55
1 x 36.82
bid
ask
-
0.52
2.21%
10:30 AM
timesize
| Ytd | 157.62% | |
| 1y | 240.16% |
22.66
day range
23.50
6.25
52 week range
34.39
| Open | 23.28 | Prev Close | 23.34 | Low | 22.66 | High | 23.50 | Mkt Cap | 3.84B |
| Vol | 168.20K | Avg Vol | 3.76M | EPS | -0.84 | P/E | N/A | Forward P/E | -14.33 |
| Beta | 1.16 | Short Ratio | 19.29 | Inst. Own | 129.07% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-04 | 50-d Avg | 27.72 | 200-d Avg | 19.23 | 1yr Est | 44.75 |
| Income Statement | |||
| Operating Expenses | 59.79M | ||
| Research and Development Expense | 37.20M | ||
| Selling, General and Administrative Expense | 22.59M | ||
| Operating Income | -59.78M | ||
| Income Tax Expense | 1000 | ||
| Net Income | -55.34M | ||
| Net Income Common Stock | -55.34M | ||
| Net Income Common Stock (USD) | -55.34M | ||
| Consolidated Income | -55.34M | ||
| Earnings per Basic Share | -0.37 | ||
| Earnings per Basic Share (USD) | -0.37 | ||
| Earnings per Diluted Share | -0.37 | ||
| Earning Before Interest & Taxes (EBIT) | -55.34M | ||
| Earning Before Interest & Taxes (USD) | -55.34M | ||
| Weighted Average Shares | 149.88M | ||
| Weighted Average Shares Diluted | 149.88M | ||
| Balance Sheet | |||
| Cash and Equivalents | 345.56M | ||
| Cash and Equivalents (USD) | 345.56M | ||
| Investments | 670.57M | ||
| Investments Current | 668.43M | ||
| Investments Non-Current | 2.14M | ||
| Current Assets | 1.03B | ||
| Property, Plant & Equipment Net | 39.76M | ||
| Total Assets | 1.07B | ||
| Debt Current | 2.94M | ||
| Total Debt | 31.99M | ||
| Current Liabilities | 20.30M | ||
| Debt Non-Current | 29.05M | ||
| Total Liabilities | 49.35M | ||
| Accumulated Retained Earnings (Deficit) | -704.01M | ||
| Accumulated Other Comprehensive Income | -633.00K | ||
| Shareholders Equity | 1.02B | ||
| Shareholders Equity (USD) | 1.02B | ||
| Assets Non-Current | 42.21M | ||
| Total Debt (USD) | 31.99M | ||
| Liabilities Non-Current | 29.05M | ||
| Trade and Non-Trade Payables | 1.81M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 1.41M | ||
| Net Cash Flow from Financing | 672.57M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 187.73M | ||
| Capital Expenditure | 20.00K | ||
| Issuance (Purchase) of Equity Shares | 672.66M | ||
| Net Cash Flow from Investing | -445.97M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -445.99M | ||
| Net Cash Flow from Operations | -38.87M | ||
| Share Based Compensation | 16.89M | ||